These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16707475)

  • 1. Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses.
    Chapatte L; Ayyoub M; Morel S; Peitrequin AL; Lévy N; Servis C; Van den Eynde BJ; Valmori D; Lévy F
    Cancer Res; 2006 May; 66(10):5461-8. PubMed ID: 16707475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High frequency of functionally active Melan-a-specific T cells in a patient with progressive immunoproteasome-deficient melanoma.
    Meidenbauer N; Zippelius A; Pittet MJ; Laumer M; Vogl S; Heymann J; Rehli M; Seliger B; Schwarz S; Le Gal FA; Dietrich PY; Andreesen R; Romero P; Mackensen A
    Cancer Res; 2004 Sep; 64(17):6319-26. PubMed ID: 15342421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M
    Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ex vivo expansion of antitumor cytotoxic lymphocytes with tumor-associated antigen-loaded dendritic cells.
    Gervais A; Bouet-Toussaint F; Toutirais O; De La Pintiere CT; Genetet N; Catros-Quemener V
    Anticancer Res; 2005; 25(3B):2177-85. PubMed ID: 16158961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs.
    Shen C; Zhang J; Xia L; Meng F; Xie W
    Cell Immunol; 2007 May; 247(1):28-35. PubMed ID: 17720150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses.
    Hirano N; Butler MO; Xia Z; Berezovskaya A; Murray AP; Ansén S; Nadler LM
    Clin Cancer Res; 2006 May; 12(10):2967-75. PubMed ID: 16707591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells.
    Stronen E; Abrahamsen IW; Gaudernack G; Wälchli S; Munthe E; Buus S; Johansen FE; Lund-Johansen F; Olweus J
    Scand J Immunol; 2009 Apr; 69(4):319-28. PubMed ID: 19284496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mature dendritic cells are superior to immature dendritic cells in expanding antigen-specific naive and memory CD8+ T cells.
    Tomiyama M; Takahara M; Egawa K; Nieda M
    Anticancer Res; 2004; 24(5C):3327-33. PubMed ID: 15515428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy.
    Li J; Mookerjee B; Wagner J
    J Immunother; 2008 Jan; 31(1):81-8. PubMed ID: 18157015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
    Batchu RB; Moreno AM; Szmania SM; Bennett G; Spagnoli GC; Ponnazhagan S; Barlogie B; Tricot G; van Rhee F
    Cancer Res; 2005 Nov; 65(21):10041-9. PubMed ID: 16267030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro antitumor lymphocyte generation using dendritic cells and innate immunity mechanisms as tumor cell treatments.
    Gervais A; Toutirais O; Bouet-Toussaint F; De la Pintiere CT; Genetet N; Catros-Quemener V
    Anticancer Res; 2007; 27(4B):2385-92. PubMed ID: 17695529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells.
    Obermann S; Petrykowska S; Manns MP; Korangy F; Greten TF
    Immunology; 2007 Sep; 122(1):90-7. PubMed ID: 17472719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells.
    Angel J; Chaperot L; Molens JP; Mezin P; Amacker M; Zurbriggen R; Grichine A; Plumas J
    Vaccine; 2007 May; 25(19):3913-21. PubMed ID: 17336432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells.
    Latouche JB; Sadelain M
    Nat Biotechnol; 2000 Apr; 18(4):405-9. PubMed ID: 10748520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promiscuity of the AlloHLA-A2 restricted T cell repertoire hampers the generation of minor Histocompatibility antigen-specific cytotoxic T cells across HLA barriers.
    Oosten LE; Blokland E; Kester MG; Falkenburg JH; van Halteren AG; Goulmy E
    Biol Blood Marrow Transplant; 2007 Feb; 13(2):151-63. PubMed ID: 17241921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
    J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.